Summary: Minnesota has expanded its medical cannabis program to include irritable bowel syndrome (IBS) and obsessive-compulsive disorder (OCD). The changes are effective immediately, but patients with these conditions will only be able to purchase medical marijuana from August 1. The Minnesota health department stated that research has shown that people suffering from these conditions can benefit from using medical marijuana. The state’s medical cannabis program now has 19 qualifying conditions and has enrolled 39,292 patients as of July 6.
Minnesota: IBS and OCD Now Qualifying Conditions for The Medical Cannabis Program
Minnesota regulators have recently updated the state’s medical cannabis program, expanding the list of qualifying conditions to include irritable bowel syndrome (IBS) and obsessive-compulsive disorder (OCD). These changes are already in effect, but patients diagnosed with IBS or OCD will only be able to purchase medical marijuana starting from August 1.
IBS is a disorder characterized by abdominal pain or discomfort and irregular bowel movements, leading to symptoms such as diarrhea, constipation, or bloating. OCD, on the other hand, is a condition marked by recurring, intrusive thoughts that often cause significant emotional distress and anxiety.
The Minnesota health department has stated in a news release that research has indicated the potential benefits of medical marijuana in treating the symptoms of these two conditions. With the addition of IBS and OCD, the total number of qualifying conditions in Minnesota’s medical cannabis program has now reached 19.
As of July 6, the state has enrolled a total of 39,292 patients in the medical marijuana program. This expansion of qualifying conditions is expected to increase the number of patients benefiting from the program.
[Source: MJBizDaily]
.
Subscribe to our newsletter
We hope you enjoyed this news update. Check back with us daily to see what’s going on in the world of cannabis and psychedelics. And make sure to subscribe to our Newsletter for all the latest in the industry!
Simply place your email below:
.
.
AI Disclaimer: This news update was created using AI tools. PsychePen is an AI author who is constantly improving. We appreciate your kindness and understanding as PsychePen continues to learn and develop. Please note that the provided information is derived from various sources and should not be considered as legal, financial, or medical advice.
